Results 11 to 20 of about 58,710 (306)

The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19

open access: yesInflammation, 2022
SARS-CoV-2 by the direct cytopathic effect or indirectly through the propagation of pro-inflammatory cytokines could cause endothelial dysfunction (ED) and oxidative stress (OS).
H. Al-kuraishy   +6 more
semanticscholar   +1 more source

Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.

open access: yesNEJM Evidence, 2022
BACKGROUND The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues.
J. O'dell   +16 more
semanticscholar   +1 more source

Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease

open access: yesAnnals of Internal Medicine, 2022
BACKGROUND Two recent randomized clinical trials of escalating doses of allopurinol for the progression of chronic kidney disease (CKD) reported no benefits but potentially increased risk for death.
Jie Wei   +11 more
semanticscholar   +1 more source

A Novel Use of Allopurinol as A Quorum-Sensing Inhibitor in Pseudomonas aeruginosa

open access: yesAntibiotics, 2021
Pseudomonas aeruginosa can cause a variety of healthcare-associated infections by its arsenal of virulence factors. Virulence factor production is largely controlled by the cell-to-cell communication system termed quorum sensing (QS). Targeting QS may be
A. A. Saqr   +5 more
semanticscholar   +1 more source

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout

open access: yesEuropean Heart Journal, 2021
Aims  With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents.
E. Kang   +4 more
semanticscholar   +1 more source

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats

open access: yesJournal of Pharmaceutical Health Care and Sciences, 2022
Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama   +5 more
doaj   +1 more source

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis

open access: yesClinical Cardiology, 2021
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. Febuxostat had a better safety outcome compared with allopurinol. In this systematic review and meta‐analysis, we searched MEDLINE and Embase for
Linggen Gao   +4 more
semanticscholar   +1 more source

Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles

open access: yesLiver international (Print), 2021
Allopurinol can cause HLA class I‐associated life‐threatening severe skin reactions. However, HLA risk and association with clinical features in allopurinol hepatotoxicity are unknown.
R. Fontana   +6 more
semanticscholar   +1 more source

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial

open access: yesJournal of International Medical Research, 2021
Objective Heart failure (HF) is a common and highly morbid cardiovascular disorder. Oxidative stress worsens HF, and uric acid (UA) is a useful oxidative stress marker.
Satoshi Suzuki   +16 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy